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Summary: Transmission dynamics of HIV-1 in Kiev were investigated using phylogenetic 
analysis of pol sequences from recently diagnosed individuals. This revealed bridging 
between the three key populations, and evidence that the sexually transmitted epidemic in 
Kiev is becoming self-sustaining. 
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Abstract  
BACKGROUND 
The HIV epidemic in Ukraine has been driven by a rapid rise among people who inject 
drugs, but recent studies have shown an increase through sexual transmission.  
METHODS 
Protease and RT sequences from 876 new HIV diagnoses (April 2013 – March 2015) in Kiev 
were linked to demographic data. We constructed phylogenetic trees for 794 subtype A1 and 
64 subtype B sequences and identified factors associated with transmission clustering. 
Clusters were defined as ≥ 2 sequences, ≥ 80% local branch support and maximum genetic 
distance of all sequence pairs in the cluster ≤ 2.5%. Recent infection was determined 
through the LAg avidity EIA assay. Sequences were analysed for transmitted drug 
resistance (TDR) mutations. 
RESULTS 
30% of subtype A1 and 66% of subtype B sequences clustered. Large clusters (maximum 
11 sequences) contained mixed risk groups. In univariate analysis, clustering was 
significantly associated with subtype B compared to A1 (OR 4.38 [95% CI 2.56-7.50]), risk 
group (OR 5.65 [3.27-9.75]) for men who have sex with men compared to heterosexual 
males, recent, compared to long-standing, infection (OR 2.72 [1.64-4.52]), reported sex work 
contact (OR 1.93 [1.07-3.47]) and younger age groups compared to age ≥36 (OR 1.83 [1.10-
3.05] for age ≤25). Females were associated with lower odds of clustering than heterosexual 
males (OR 0.49 [0.31-0.77]). In multivariate analysis, risk group, subtype and age group 
were independently associated with clustering (p<0.001, p=0.007 and p=0.033). 18 
sequences (2.1%) indicated evidence of TDR. 
CONCLUSIONS 
Our findings suggest high levels of transmission and bridging between risk groups. 
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INTRODUCTION 
With an estimated 238,000 people living with HIV/AIDS, and AIDS-related annual mortality of 
around 17,000, Ukraine is experiencing one of the most severe HIV epidemics in Europe (1).  
The initial epidemic followed a rapid rise of illegal drug use after the breakup of the Soviet 
Union. By 1996 there were 12,000 HIV infections diagnosed a year, mainly in people who 
inject drugs (PWID), but from late 1990s sexually-transmitted infections, and infections in 
children, increased (2, 3). Since 2006, new diagnoses among PWID fell, and from 2008 the 
majority have been through sexual contacts, most believed to be linked to PWID (1, 4, 5). 
Diagnoses among men who have sex with men (MSM) are low in official statistics but other 
studies have shown these figures to be under-estimated (6-8).  
Previous studies recommend interventions targeting bridge populations (sexual partners of 
PWID, clients of sex workers, and female partners of MSM), responsible for linking high risk 
groups with the general population (1, 9-11).  The prevention programs delivered through the 
International HIV/AIDS Alliance in Ukraine since 2006 have increased opioid substitution 
therapy, HIV testing and counselling, access to health services and antiretroviral therapy 
(ART) coverage, but continued efforts are required to reach WHO targets (1). Currently there 
is no government support for prevention programs and financial resources are limited due to 
ongoing armed conflict in parts of the country.  
We examined HIV transmission dynamics in Ukraine using viral sequences. Previous studies 
have used phylogenetic analysis of HIV-1 sequences from Ukraine and other former Soviet 
Union (FSU) countries to describe the molecular epidemiology of HIV-1 in Ukraine from 
earlier years (2, 12, 13-16). Ours is the first using phylogenetics to examine new diagnoses 
and recently-acquired infection, and is unique in having a large number of HIV-1 sequences 
with detailed demographic data.  
Sequences obtained from samples collected in the Kiev region between April 2013 and 
March 2015 were analysed to identify clusters of closely-related infections, and to 
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characterise factors associated with high levels of ongoing transmission. We examined 
bridge groups by describing the association and separation of risk groups within 
transmission clusters.  
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METHODS 
Study Population and Data Collection 
This analysis used data collected in a larger study within the CASCADE Collaboration in 
EuroCoord (www.EuroCoord.net), which estimated HIV incidence in Kiev. The study 
population and data collection methods were described in detail in earlier publications (17, 
18). Briefly, data were collected from all persons over the age of 16 who presented or were 
referred for an HIV test at any of the four infectious disease clinics in the Kiev province 
(known collectively as Kiev City AIDS Centre), between 1st April 2013 and 29th March 2015. 
Tests from routine screening programmes, for example antenatal screening and blood 
donation, were excluded due to different incidence estimation methods in these programs. 
Tests from general screening, for example, surgical interventions, army recruitment, 
prisoners and visa applications were included.  
Data collected from an anonymous questionnaire included year of birth, area of residence, 
sex, reason for test, risk factors for HIV including likely route of infection, and testing history. 
A number of individuals with long-standing HIV infections, sampled to assess the false 
recent rate of the recent testing algorithm (RITA) in the main study, were included for 
phylogenetic robustness but did not complete the survey and were not included in the 
analysis of factors associated with clustering.   
Laboratory Methods 
HIV positive residual blood samples were tested for recent infection, using the limiting 
antigen (LAg) avidity EIA assay at Public Health England. For those classified as recent 
(infections likely to have occurred within the last six months), HIV viral load (VL) was 
quantified, and those with low VL (<1000 copies/mL) were reclassified as longstanding. 
Methods are described in detail by Simmons et al (17).  
In HIV pol gene sequencing, nucleic acid extraction followed by nested PCR (outer forward 
and reverse primers AATGATGACAGCATGYCAGGGAGT and 
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AGTCTTTCCCCATATTACTATGCTTTC, inner forward and reverse primers 
GGAAAAAGGGCTGTTGGAAATGTG and GGCTCTTGATAAATTTGATATGTCCAT) 
amplified a pol gene product which was then sequenced on Sanger or Illumina Miseq 
platforms. 
Phylogenetic Methods 
Sequences were aligned using MPAlign (19) and positions 1-1320 retained. Rega3 
subtyping was performed (20). Sequences were examined for transmitted drug resistance 
(TDR), according to the World Health Organization (WHO) 2009 surveillance list (21). 
Maximum-likelihood trees were created in Fasttree 2.1 (22) for subtypes A1 and B with the 
General Time Reversal method of nucleotide substitution (GTR), which excluded nucleotide 
ambiguity codes. 1130 subtype A, and 230 subtype B sequences from FSU countries 
between 2010 and 2014, were included from the Los Alamos Database to increase 
phylogenetic robustness.  
Analysis of clusters was performed using programs written in R. Fasttree SH local branch 
support values of ≥80%, and a maximum genetic distance of 2.5% between all sequence 
pairs were used to identify clusters. Nucleotide ambiguity codes were included only if they 
generated a definite change (e.g. A to S). The 2.5% threshold was calculated using a 
modified version of an approach described by Aldous et al (23) as follows: we created 1000 
randomly generated clusters, sizes 2-50, from the combined FSU and Kiev sequences, and 
calculated the maximum pairwise genetic distance in each cluster. The distance of 2.5% fell 
below the 0.01 percentile of the distribution of these values, making it highly unlikely that 
clusters with a maximum genetic distance of this value or below would occur by chance in 
phylogenetically unrelated sequences.  
Data Preparation/Management 
Survey data were linked to laboratory results. Age at diagnosis was grouped in four bands: 
≤25, 26-30, 31-35 and ≥36 years. Risk group was based on survey questions (have you ever 
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injected drugs, had sex with a person of the opposite sex, had sex with someone of the 
same sex, paid for sex, been paid for sex) and categorised in the following hierarchical order 
(if more than one was reported): PWID, MSM or heterosexual contact. ‘Sex worker/contact 
with sex worker’ was based on responses to ‘ever paid for’ and/or ‘ever been paid for sex’. 
Reason for test was categorised as either clinical indication (symptoms), high risk group (has 
injected drugs, has multiple partners, had a sexually transmitted infection (STI), had a 
needle stick injury, had contact with an HIV-positive person, suspects they are HIV-positive), 
or general screening (described above). A hierarchy was applied as follows if multiple 
reasons were recorded: screening, clinical indication, high risk group. Repeat testing was 
defined as having at least one prior HIV test result more than one month before the current 
test. 
Statistical Analysis of factors associated with clustering 
All sequences were categorised as clustering or not clustering. To assess associations with 
clustering, we performed univariate and multivariate logistic regression analysis, controlling 
for the following variables: sex, age group, subtype, assigned risk group, reported sex 
work/contact with sex worker, repeated testing history, recent or longstanding infection, and 
reason for test. All variables which were significantly associated with the outcome (p≤0.05) in 
univariate analyses were assessed in the multivariate models. We used a forwards stepwise 
approach so that variables were retained in the model if they significantly improved the fit of 
the model (p≤0.05, based on likelihood ratio tests). To avoid collinearity, sex and the 
assigned risk group variables are reported under one variable, categorised as MSM, 
Heterosexual Contact: Male, Heterosexual Contact: Female, PWID: Male, PWID: Female. 
Clusters were assigned to a group, based on reported route of exposure of over 60% of 
samples in the cluster belonging to a particular risk group or combination of risk groups, in 
the following hierarchical way; 1) MSM 2) Heterosexual contact: Male and female, 3) PWID: 
Male and female, 4) Male heterosexual alone or with MSM 5) Heterosexual contact and 
PWID mixed. Groups with no data on ≥40% of samples were recorded as missing. Using a 
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method described by Poon et al (24), we also examined the association and separation of 
different risk groups within clusters:  multiple scatterplot diagrams of all clusters were 
created, where each point represented a cluster, with the area of the marker scaled to 
cluster size. The x and y axis denoted pairs of risk groups, and the location of the marker 
showed the proportion of samples in the cluster belonging to each of the risk groups. 
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RESULTS 
Study Population Characteristics 
During the study period, 1192 persons tested positive for HIV in the Kiev region. Sequences 
were obtained from 898 of these samples (294 samples were not received by the laboratory, 
or failed to amplify/contained insufficient sample volume). Sample pairs with identical 
sequences (after removing resistance positions) were manually checked for matching 
demographic data, and 22 samples were identified as duplicates and excluded.  
Among the remaining 876 samples, most (794, 91%) were subtype A1 and 64 (7%) were 
subtype B; the remaining 18 samples comprised a mixture of subgroups 02_AG, G, 03_AB 
and other recombinants. Only the 858 subtype A1 and B samples were included in the 
analysis (Table 1). Of these, 54 samples could not be linked to survey data and had no 
demographic data. A further 41 samples were missing data on one or more of the following 
variables; risk group, recent infection, repeat tester, sex work/contact with sex worker and 
reason for test.  
The majority of individuals were male (71%) with assigned source of infection being 
heterosexual sex (52%). 37% were assigned as PWID, the majority male (83%), and 11% 
were assigned as MSM. Of 794 samples with risk group data, 48 (6%) reported that they had 
been paid, or had paid for sex. The median age was 33, IQR: 29-38. We found a significant 
difference in risk group category between the 876 sequenced and 294 un-sequenced 
samples. Sequenced data had a higher proportion of MSM (11% compared to 6%) and 
heterosexual males (29% compared to 20%) and a lower proportion of female PWID (7% 
compared to 13%), p < 0.001.  
From 795 samples with results, 67 (8%) were identified as recent infections. Individuals 
assigned as MSM were more likely to have a recent infection compared to individuals 
assigned to heterosexual transmission (OR 4.81 [95% CI 2.69-8.60] p < 0.001) while PWID 
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were less likely to have a recent infection compared to heterosexuals (OR 0.39 [95% CI 
0.18-0.83] p = 0.015) in a univariate logistic regression model. 
The majority of individuals reported the reason for test as either high risk behaviours (47%) 
or clinical indication (47%). 
Drug Resistance Mutations 
18/858 (2.1%) samples contained drug resistance mutations, indicating TDR, as follows; 3 
with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, 4 with nucleoside 
reverse transcriptase inhibitor (NRTI), 5 with NRTI and NNRTI resistance, 1 with NRTI and 
protease inhibitor (PI) resistance, and 5 with only PI resistance.  
Factors Associated With Clustering 
A third of the sequences appeared in clusters of size 2 or above. Clustering was higher in 
subtype B, with 42/64 sequences clustering (66%) compared to 241/794 (30%) in subtype 
A1. This additional subtype B clustering was mainly among heterosexual males, with 69% 
clustering compared to 30% in subtype A1. 
In univariate analyses (Table 1), clustering was significantly associated with the following: 
subtype B compared to subtype A1 (OR 4.38 [95% CI 2.56-7.50]), younger age groups 
compared to over 35s (OR 1.83 [1.10-3.05], for age ≤25 and OR 2.09 [1.42—3.07] for age 
26-30), MSM compared to heterosexual males (OR 5.65 [3.27-9.75]), recent compared to 
long-standing infection (OR 2.72 [1.64-4.52]), and reported sex work or contact with a sex 
worker (OR 1.93 [1.07-3.47]). Testing due to clinical indication, compared to high risk 
behaviours also showed higher levels of clustering although this was not significant at the 
5% level. Lower levels of clustering were seen in heterosexual females compared to 
heterosexual males (OR 0.49 [0.31-0.77]), but not in female compared to male PWIDs (OR 
0.89 [0.45-1.77]). 
Page 12  
 
In the multivariate analysis, subtype, age group, and risk group remained independently 
associated with clustering. As well as MSM, female heterosexuals remained significantly 
less likely to cluster compared to heterosexual males (adjusted OR (aOR) 0.51 [0.32-0.81]). 
When separating sex and risk group, both remained independently associated with 
clustering, with males more likely to cluster than females (aOR 1.94 [1.27-2.95]) and MSM 
more likely to cluster than heterosexuals (aOR 4.31 [2.40-7.75]).  
Cluster Analysis 
The 283 samples which clustered formed 93 subtype A1 (Fig 1) and 13 subtype B (Fig 2) 
clusters. Almost half (48%) clustered in pairs. The remainder formed 35 clusters of sizes 3-5, 
and three larger clusters; one of 6 subtype B sequences, and two subtype A1 clusters of 9 
and 11 sequences. Over a third of clusters, including the largest three, were predominantly 
MSM, or MSM and heterosexual male. Categories PWID and PWID and heterosexual 
combined accounted for 38 clusters, mainly pairs, and 18 clusters (17 pairs) were classified 
as heterosexual. The remainder (6 clusters) were missing data (Fig 3). 
The scatterplots (Fig 4) showed that association of risk groups within clusters was greatest 
between MSM and heterosexual male, followed by heterosexual and PWID risk groups. 
Separation was greatest between MSM and samples from females. 
There was no evidence of clustering among sequences containing drug resistance 
mutations. 
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DISCUSSION 
In this analysis, we have characterised recent transmission patterns in Kiev, showing high 
levels of clustering, in well-supported branches with low intra-cluster variability.  
It has been widely reported that the epidemic among PWID in Ukraine is shifting, with 
increasing numbers of infections being attributable to sexual contact (10, 11, 25). Our 
findings support this, with lower levels of clustering in PWID compared to heterosexual 
males, and PWID less likely to have a recent infection than individuals reporting 
heterosexual contact (17), although levels of clustering in heterosexual males may be 
overstated due to non-disclosure from MSM or PWID.  
Clustering in heterosexual females was significantly lower than that in heterosexual males, 
and the majority appeared in small clusters, with male PWID or other female heterosexuals. 
High numbers of females have previously reported sexual contact with PWID (18), and while 
clustering is lower in PWID than other risk groups, there is still evidence of bridging between 
male PWID and their female partners. PWID remain a hard to reach group in Ukraine, with 
the criminal nature of drug taking leading to non-disclosure and interventions reaching only a 
small proportion of estimated numbers (26).  
Clustering among MSM was strikingly high, with the majority of clusters, including the largest 
three, containing mainly MSM, or combinations of MSM and heterosexual males. It is likely 
that this reflects high levels on ongoing transmission among MSM. A 2006 epidemiological 
review estimated Ukraine to have around 27% HIV prevalence among MSM compared to 
less than 2% in other adults (27), although official estimates are considerably less and may 
reflect under-reporting (28). Recent MSM HIV incidence estimates in Kiev are between 2290 
and 6869 per 100,000 compared to 21.5 per 100,000 in the general population (17). There 
are also high levels of recent infection among MSM with approximately one in four new 
diagnoses in Odessa and Kiev shown to be recently infected, and MSM disproportionately 
represented in both new diagnoses and recent infection (17, 18, 29). A 2011 bio-behavioural 
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study of MSM in Ukraine showed low HIV testing rates, limited access to prevention 
programs, and high levels of sexual mixing with female heterosexuals, and with sex workers 
of both sexes (30).  
Subtype B clustering was higher than subtype A1 after accounting for risk group. The 
subtype B variant in Ukraine (IDU-B) was less epidemiologically successful than A1, and 
although it remains prevalent, has not spread widely to other countries of the FSU (3). 
Subtype B samples were also less likely to cluster with background FSU samples compared 
to subtype A1. This suggests greater coverage of subtype B in our data which could explain 
some additional clustering. Being mainly MSM and heterosexual male, subtype B samples 
may include more recent transmissions than subtype A1. However, as all of the additional 
clustering in subtype B was among heterosexual males, it may be that the main contributory 
factor is high levels of undisclosed MSM in this group.    
Younger age of sexual activity has been associated with an increased risk of HIV infection 
(27) and we found higher levels of clustering in younger age groups. A recent study in 
Odessa showed a higher risk of recent infection among younger people (29) and younger 
adults in our data were more likely to be recently-infected (17) 
We found low levels of TDR (2.1%), which would be expected as estimated ART coverage in 
Ukraine is low at 22% (26).  Previous TDR estimates have been higher (31, 32) but have 
used different definitions of TDR mutations from ours, in particular the inclusion of accessory 
NRTI mutation A62V, a reported polymorphism in non-B subtypes. (33, 34). 
There are a number of limitations to consider. As this data is from relatively recent samples, 
data coverage is not complete, and sampling density may be markedly different for different 
populations within the dataset due to variable testing patterns. Much of the data is self-
reported, and there may be significant levels of non-disclosure, particularly among MSM, 
indicated by high levels of clustering between MSM and males reporting heterosexual 
contact. In addition undiagnosed HIV rates are likely to be high and may vary between 
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populations. Our data are unlikely to be representative of the whole of Ukraine. Transmission 
patterns may vary in other areas of the country as there is considerable variability in HIV 
prevalence and population size of different risk groups (35). Differences between sequenced 
and un-sequenced data is a potential source of bias. Both MSM and heterosexual males 
were overrepresented in the sequenced data which may have improved our ability to detect 
clustering in these groups. 
This study supports previous reports of the transition of the HIV-1 epidemic in Ukraine from 
PWID to the non-drug using population, through the sexual partners of PWID and MSM. 
High levels of recent infections in MSM, high clustering among MSM, and bridging between 
MSM and reported heterosexuals in recently-diagnosed people suggest that this sexually-
transmitted epidemic may have become self-sustaining. This highlights the need for 
continued efforts to reach the MSM and PWID populations, and their partners, with targeted 
interventions to reduce the risk of onwards transmission.  
 
  
Page 16  
 
Appendix 
CASCADE Steering Committee: Julia Del Amo (Chair), Laurence Meyer (Vice Chair), 
Heiner C. Bucher, Geneviève Chêne, Osamah Hamouda, Deenan Pillay, Maria Prins, 
Magda Rosinska, Caroline Sabin, Giota Touloumi. 
CASCADE Co-ordinating Centre: Kholoud Porter (Project Leader), Ashley Olson, Andrea 
Cartier, Lorraine Fradette, Sarah Walker, Abdel Babiker. 
CASCADE Clinical Advisory Board: Heiner C. Bucher, Andrea De Luca, Martin Fisher, 
Roberto Muga 
CASCADE Collaborators: Australia PHAEDRA cohort (Tony Kelleher, David Cooper, Pat 
Grey, Robert Finlayson, Mark Bloch) Sydney AIDS Prospective Study and Sydney Primary 
HIV Infection cohort (Tony Kelleher, Tim Ramacciotti, Linda Gelgor, David Cooper, Don 
Smith); Austria Austrian HIV Cohort Study (Robert Zangerle); Canada South Alberta clinic 
(John Gill); Estonia Tartu Ülikool (Irja Lutsar); France ANRS CO3 Aquitaine cohort 
(Geneviève Chêne, Francois Dabis, Rodolphe Thiebaut), ANRS CO4 French Hospital 
Database (Dominique Costagliola, Marguerite Guiguet), Lyon Primary Infection cohort 
(Philippe Vanhems), French ANRS CO6 PRIMO cohort (Marie-Laure Chaix, Jade Ghosn), 
ANRS CO2 SEROCO cohort (Laurence Meyer, Faroudy Boufassa); Germany German HIV-1 
seroconverter cohort (Osamah Hamouda, Karolin Meixenberger, Norbert Bannert, Barbara 
Bartmeyer); Greece AMACS (Anastasia Antoniadou, Georgios Chrysos, Georgios L. 
Daikos); Greek Haemophilia cohort (Giota Touloumi, Nikos Pantazis, Olga Katsarou); Italy 
Italian Seroconversion Study (Giovanni Rezza, Maria Dorrucci), ICONA cohort (Antonella 
d’Arminio Monforte, Andrea De Luca.) Netherlands Amsterdam Cohort Studies among 
homosexual men and drug users (Maria Prins, Ronald Geskus, Jannie van der Helm, 
Hanneke Schuitemaker); Norway Oslo and Ulleval Hospital cohorts (Mette Sannes, 
Oddbjorn Brubakk, Anne-Marte Bakken Kran); Poland National Institute of Hygiene 
(Magdalena Rosinska); Spain Badalona IDU hospital cohort (Roberto Muga, Jordi Tor), 
Page 17  
 
Barcelona IDU Cohort (Patricia Garcia de Olalla, Joan Cayla), CoRIS-scv (Julia del Amo, 
Santiago Moreno, Susana Monge); Madrid cohort (Julia Del Amo, Jorge del Romero), 
Valencia IDU cohort (Santiago Pérez-Hoyos); Sweden Swedish InfCare HIV Cohort, Sweden 
(Anders Sönnerborg); Switzerland Swiss HIV Cohort Study (Heiner C. Bucher, Huldrych 
Günthard, Alexandra Scherrer); Ukraine Perinatal Prevention of AIDS Initiative (Ruslan 
Malyuta); United Kingdom Public Health England (Gary Murphy), UK Register of HIV 
Seroconverters (Kholoud Porter, Anne Johnson, Andrew Phillips, Abdel Babiker), University 
College London (Deenan Pillay); African cohorts: Genital Shedding Study (US: Charles 
Morrison; Family Health International, Robert Salata, Case Western Reserve University, 
Uganda: Roy Mugerwa, Makerere University, Zimbabwe: Tsungai Chipato, University of 
Zimbabwe); International AIDS Vaccine Initiative (IAVI) Early Infections Cohort (Kenya, 
Rwanda, South Africa, Uganda, Zambia: Matt A. Price, IAVI, USA; Jill Gilmour, IAVI, UK; 
Anatoli Kamali, IAVI, Kenya; Etienne Karita, Projet San Francisco, Rwanda). 
EuroCoord Executive Board: Fiona Burns, University College London, UK; Geneviève 
Chêne, University of Bordeaux, France; Dominique Costagliola (Scientific Coordinator), 
Institut National de la Santé et de la Recherche Médicale, France; Carlo Giaquinto, 
Fondazione PENTA, Italy; Jesper Grarup, Region Hovedstaden, Denmark; Ole Kirk, Region 
Hovedstaden, Denmark; Laurence Meyer, Institut National de la Santé et de la Recherche 
Médicale, France; Heather Bailey, University College London, UK; Alain Volny Anne, 
European AIDS Treatment Group, France; Alex Panteleev, St. Petersburg City AIDS Centre, 
Russian Federation; Andrew Phillips, University College London, UK, Kholoud Porter, 
University College London, UK; Claire Thorne, University College London, UK. 
EuroCoord Council of Partners: Jean-Pierre Aboulker, Institut National de la Santé et de la 
Recherche Médicale, France; Jan Albert, Karolinska Institute, Sweden; Silvia Asandi, 
Romanian Angel Appeal Foundation, Romania; Geneviève Chêne, University of Bordeaux, 
France; Dominique Costagliola (chair), INSERM, France; Antonella d’Arminio Monforte, 
ICoNA Foundation, Italy; Stéphane De Wit, St. Pierre University Hospital, Belgium; Peter 
Page 18  
 
Reiss, Stichting HIV Monitoring, Netherlands; Julia Del Amo, Instituto de Salud Carlos III, 
Spain; José Gatell, Fundació Privada Clínic per a la Recerca Bíomèdica, Spain; Carlo 
Giaquinto, Fondazione PENTA, Italy; Osamah Hamouda, Robert Koch Institut, Germany; 
Igor Karpov, University of Minsk, Belarus; Bruno Ledergerber, University of Zurich, 
Switzerland; Jens Lundgren, Region Hovedstaden, Denmark; Ruslan Malyuta, Perinatal 
Prevention of AIDS Initiative, Ukraine; Claus Møller, Cadpeople A/S, Denmark; Kholoud 
Porter, University College London, United Kingdom; Maria Prins, Academic Medical Centre, 
Netherlands; Aza Rakhmanova, St. Petersburg City AIDS Centre, Russian Federation; 
Jürgen Rockstroh, University of Bonn, Germany; Magda Rosinska, National Institute of 
Public Health, National Institute of Hygiene, Poland; Manjinder Sandhu, Genome Research 
Limited; Claire Thorne, University College London, UK; Giota Touloumi, National and 
Kapodistrian University of Athens, Greece; Alain Volny Anne, European AIDS Treatment 
Group, France. 
EuroCoord External Advisory Board: David Cooper, University of New South Wales, 
Australia; Nikos Dedes, Positive Voice, Greece; Kevin Fenton, Public Health England, USA; 
David Pizzuti, Gilead Sciences, USA; Marco Vitoria, World Health Organisation, Switzerland. 
EuroCoord Secretariat: Silvia Faggion, Fondazione PENTA, Italy; Lorraine Fradette, 
University College London, UK; Richard Frost, University College London, UK; Andrea 
Cartier, University College London, UK; Dorthe Raben, Region Hovedstaden, Denmark; 
Christine Schwimmer, University of Bordeaux, France; Martin Scott, UCL European 
Research & Innovation Office, UK. 
  
Page 19  
 
Funding: This work was supported by the European Union Seventh Framework Programme 
(FP7/2007-2013) under EuroCoord [grant agreement number 260694]. 
RBF received funding related to this study from the NIHR Biomedical Research Centre and 
the UCLH/UCL BRC funded NIHR Health Informatics Collaborative study. 
Acknowledgements 
Assistance in data retrieval was provided by Lorraine Fradette, University College London, 
and Andrea Cartier, University College London. 
 
 
  
Page 20  
 
References 
1. World Health Organisation. Good practices in Europe: HIV prevention for People 
Who Inject Drugs implemented by the International HIV/AIDS Alliance in Ukraine. 
2014. 
2. Saad MD, Shcherbinskaya AM, Nadai Y, et al. Molecular epidemiology of HIV Type 1 
in Ukraine: birthplace of an epidemic. AIDS Research and Human Retroviruses 2006; 
22(8): 709-14. 
3. Bobkova M. Current status of HIV-1 diversity and drug resistance monitoring in the 
former USSR. AIDS Reviews 2013; 15(4): 204-12. 
4. Malyuta R. Curbing HIV incidence in people who inject drugs. The Lancet HIV 2016; 
3(10):e453-4. 
5. Des Jarlais DC, Feelemyer JP, Modi SN, et al. Transitions from injection-drug-use-
concentrated to self-sustaining heterosexual HIV epidemics: patterns in the 
international data. PloS One 2012; 7(3): e31227. 
6. Marcus U, Hickson F, Weatherburn P, Schmidt AJ, Network E. Estimating the size of 
the MSM populations for 38 European countries by calculating the survey-
surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the 
European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses 
among MSM in 2009. BMC Public Health 2013; 13: 919. 
7. UNAIDS. Hidden HIV epidemic amongst MSM in Eastern Europe and Central Asia. 
Available at: 
http://www.unaids.org/en/resources/presscentre/featurestories/2009/january/2009012
6msmukraine. Accessed 23/08/2016. 
8. Cakalo JI, Bozicevic I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. 
Misclassification of men with reported HIV infection in Ukraine. AIDS and Behavior 
2015; 19(10): 1938-40. 
Page 21  
 
9. Hamers FF, Batter V, Downs AM, Alix J, Cazein F, Brunet JB. The HIV epidemic 
associated with injecting drug use in Europe: geographic and time trends. AIDS 
1997; 11(11): 1365-74. 
10. Hamers FF, Downs AM. HIV in central and eastern Europe. Lancet 2003; 361(9362): 
1035-44. 
11. Mazhnaya A, Andreeva TI, Samuels S, DeHovitz J, Salyuk T, McNutt LA. The 
potential for bridging: HIV status awareness and risky sexual behaviour of injection 
drug users who have non-injecting permanent partners in Ukraine. Journal of the 
International AIDS Society 2014; 17: 18825. 
12. Novitsky VA, Montano MA, Essex M. Molecular epidemiology of an HIV-1 subtype A 
subcluster among injection drug users in the Southern Ukraine. AIDS Research and 
Human Retroviruses 1998; 14(12): 1079-85. 
13. Nabatov AA, Kravchenko ON, Lyulchuk MG, Shcherbinskaya AM, Lukashov VV. 
Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug 
users in southern Ukraine at the beginning of the epidemic in the former Soviet 
Union. AIDS Research and Human Retroviruses 2002; 18(12): 891-5. 
14. Diez-Fuertes F, Cabello M, Thomson MM. Bayesian phylogeographic analyses clarify 
the origin of the HIV-1 subtype A variant circulating in former Soviet Union's 
countries. Infection, genetics and evolution : Journal of Molecular Epidemiology and 
Evolutionary Genetics in Infectious Diseases 2015; 33: 197-205. 
15. Thomson MM, de Parga EV, Vinogradova A, et al. New insights into the origin of the 
HIV type 1 subtype A epidemic in former Soviet Union's countries derived from 
sequence analyses of preepidemically transmitted viruses. AIDS Research and 
Human Retroviruses 2007; 23(12): 1599-604. 
16. Riva C, Romano L, Saladini F, et al. Identification of a possible ancestor of the 
subtype A1 HIV Type 1 variant circulating in the former Soviet Union. AIDS Research 
and Human Retroviruses 2008; 24(10): 1319-25. 
Page 22  
 
17. Simmons R, Malyuta R, Chentsova N, et al. HIV Incidence Estimates Using the 
Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014. 
PloS One 2016; 11(6): e0157179. 
18. Simmons R, Malyuta R, Chentsova N, et al. HIV Testing and Diagnosis Rates in 
Kiev, Ukraine: April 2013-March 2014. PloS One 2015; 10(8): e0137062. 
19. Gaschen B, Kuiken C, Korber B, Foley B. Retrieval and on-the-fly alignment of 
sequence fragments from the HIV database. Bioinformatics 2001; 17(5): 415-8. 
20. Pineda-Pena AC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic 
sequences for clinical and surveillance purposes: performance evaluation of the new 
REGA version 3 and seven other tools. Infection, genetics and evolution : Journal of 
Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases 2013; 19: 
337-48. 
21. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance 
of transmitted HIV-1 drug-resistance: 2009 update. PloS One 2009; 4(3): e4724. 
22. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees 
for large alignments. PloS One 2010; 5(3): e9490. 
23. Aldous JL, Pond SK, Poon A, et al. Characterizing HIV transmission networks across 
the United States. Clinical Infectious Diseases 2012; 55(8): 1135-43. 
24. Poon AF, Joy JB, Woods CK, et al. The impact of clinical, demographic and risk 
factors on rates of HIV transmission: a population-based phylogenetic analysis in 
British Columbia, Canada. The Journal of Infectious Diseases 2015; 211(6): 926-35. 
25. Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central 
and Eastern Europe. International journal of STD & AIDS 2003; 14(6): 361-71. 
26. World Health Organisation. HIV/AIDS treatment and care in Ukraine: Evaluation 
report., April 2013. 
27. Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts-
-16th International AIDS Conference epidemiology plenary. Clinical Infectious 
Diseases 2007; 44(7): 981-7. 
Page 23  
 
28. European Centre for Disease Prevention and Control, Europe. WROf. HIV/AIDS 
surveillance in Europe 2014. Stockholm: ECDC. 2015. 
29. Simmons R, Semenenko I, Tolpina M, et al. High percentage of recent HIV infection 
leading to onward transmission in Odessa, Ukraine associated with young adults. 
AIDS and Behavior 2014; 18(2): 411-8. 
30. Bolshov YS KM, Leshchynskyi YB, Trofymenko LV, Shvab IA. Analytical report: 
behaviour monitoring and HIV prevalence among men who have sex with men as a 
component of second generation surveillance based on results of the biobehavioural 
survey of 2011. Kyiv: International HIV/AIDS Alliance in Ukraine, 2012. Available: 
http://www.aidsalliance.org.ua/ru/library/our/2012/me/msm_en_2011.pdf Accessed 
15 Mar, 2017. 
31. Chan PA, Kantor R. Transmitted drug resistance in nonsubtype B HIV-1 infection. 
HIV Therapy 2009; 3(5): 447-65. 
32. Vazquez de Parga E, Rakhmanova A, Perez-Alvarez L, et al. Analysis of drug 
resistance-associated mutations in treatment-naive individuals infected with different 
genetic forms of HIV-1 circulating in countries of the former Soviet Union. Journal of 
Medical Virology 2005; 77(3): 337-44. 
33. Lai MT, Lu M, Felock PJ, et al. Distinct mutation pathways of non-subtype B HIV-1 
during in vitro resistance selection with nonnucleoside reverse transcriptase 
inhibitors. Antimicrobial Agents and Chemotherapy 2010; 54(11): 4812-24. 
34. Singh K, Flores JA, Kirby KA, et al. Drug resistance in non-B subtype HIV-1: impact 
of HIV-1 reverse transcriptase inhibitors. Viruses 2014; 6(9): 3535-62. 
35. Zaller N, Mazhnaya A, Larney S, et al. Geographic variability in HIV and injection 
drug use in Ukraine: implications for integration and expansion of drug treatment and 
HIV care. The International Journal on Drug Policy 2015; 26(1): 37-42. 
 
  
Page 24  
 
Table 1.  Factors associated with clustering from HIV-1 pol sequences collected in Kiev April 
2013-March 2015 
 
 
 
 
 
 
 
 
 
Univariate Multivariate
All (%) Clustered (%) OR (95% CI) P value aOR (95% CI) P value
All 858 283 33%
Subtype 858
A1 794 93% 241 30% 1 1
B 64 7% 42 66% 4.38 (2.56-7.50) <0.001 2.41 (1.28-4.54) 0.007
Sex 804
Female 234 29% 50 21% 1
Male 570 71% 215 38% 2.23 (1.56-3.18) <0.001
Age (Years) 804
<= 25 83 10% 34 41% 1.83 (1.10-3.05) < 0.001 1.39 (0.78-2.49)
26 - 30 199 25% 88 44% 2.09 (1.42-3.07) 1.75 (1.15-2.65) 0.033
31 - 35 249 31% 68 27% 1.00 (0.67-1.46) 1.02 (0.68-1.53)
>= 36 273 34% 75 27% 1 1
Risk Group 794
Heterosexual Male 230 29% 79 34% 1 1
Heterosexual Female 181 23% 37 20% 0.49 (0.31-0.77) 0.51 (0.32-0.81) <0.001
PWID: Male 241 30% 67 28% 0.74 (0.50-1.09) 0.82 (0.55-1.23)
PWID: Female 51 6% 13 25% 0.65 (0.33-1.30) 0.68 (0.34-1.38)
MSM 91 11% 68 75% 5.65 (3.27-9.75) <0.001 4.36 (2.48-7.67) <0.001
Recent Infection 795
No 728 92% 227 31% 1
Yes 67 8% 37 55% 2.72 (1.64-4.52) <0.001
Repeat Tester 796
No 678 85% 226 33% 1
Yes 118 15% 39 33% 0.99 (0.65-1.50) 0.990
Sex worker/contact with sex worker 794
No 746 94% 274 37% 1
Yes 48 6% 24 50% 1.93 (1.07-3.47) 0.028
Reason for test 763
High risk behaviours 361 47% 112 31% 1
Screening 46 6% 11 24% 0.70 (0.34-1.43)
Clinical indicators 356 47% 130 37% 1.27 (0.94-1.74) 0.120
CI Confidence interval
aOR Adjusted odds ratio
PWID People who inject drugs
MSM Men who have sex with men
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Figure 1. 
   
Figure 1.  Subtype A1 phylogeny (clusters of size 4 and above), HIV-1 pol sequences 
collected in Kiev April 2013-March 2015. 
Subtype A1 clusters sizes 4 and above only. Individual clusters are highlighted and coloured 
according to the risk group of over 60% of samples in the cluster (see figure 3) 
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Figure 2. 
 
  
Figure 2.  Subtype B phylogeny (all clusters), HIV-1 pol sequences collected in Kiev April 
2013-March 2015. 
Subtype B clusters all sizes. Individual clusters are highlighted and coloured according to the 
risk group of over 60% of samples in the cluster (see figure 3) 
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Figure 3.   
 
 
Figure 3.  Clusters by risk group. Subtype A1 and B HIV-1 pol sequences collected in Kiev 
April 2013-March 2015. 
Groups based on >60% of samples in the cluster. 
Abbreviations: MSM, Men who have sex with men; HetM/MSM, Heterosexual males (sexual 
contact and PWID) and MSM; Het, Heterosexual sexual contact (male and female); PWID, 
People who inject drugs (male and female); Het/PWID, Heterosexual sexual contact (male 
and female) and PWID (male and female) 
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Figure 4. 
 
Figure 4.  Scatter plot of association of risk groups within clusters. Subtype A1 and B HIV-1 
pol sequences collected in Kiev April 2013-March 2015 
On each graph, points represent every cluster, with the marker scaled to cluster size. The x 
and y axis denote risk groups, and the location of the marker shows the proportion of 
sequences in the cluster belonging to each of the risk groups. 
Abbreviations: MSM, Men who have sex with men; PWID, People who inject drugs 
 
